Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to ...

T here is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...

The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...

The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...

After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...

A higher dividend yield is nice because it allows you to collect more dividend income on every dollar you invest in a stock.

The neurovascular market, estimated at $4.2bn in 2024 by GlobalData, is becoming increasingly specialised and competitive.

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...

Medtronic's FDA-approved BrainSense Adaptive DBS system revolutionizes Parkinson's therapy with real-time adjustments for ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...